BiotechTube

EDP-420 / Duration of Treatment - 3 days + Telithromycin / Duration of Treatment - 7 days

Phase 2UNKNOWN
1 views this week 0 watching💤 Quiet
Interest: 21/100
21
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Community Acquired Pneumonia

Conditions

Community Acquired Pneumonia

Trial Timeline

Dec 1, 2005 → Jul 1, 2007

NCT ID
NCT00270517

About EDP-420 / Duration of Treatment - 3 days + Telithromycin / Duration of Treatment - 7 days

EDP-420 / Duration of Treatment - 3 days + Telithromycin / Duration of Treatment - 7 days is a phase 2 stage product being developed by Enanta Pharmaceuticals for Community Acquired Pneumonia. The current trial status is unknown. This product is registered under clinical trial identifier NCT00270517. Target conditions include Community Acquired Pneumonia.

What happened to similar drugs?

2 of 13 similar drugs in Community Acquired Pneumonia were approved

Approved (2) Terminated (2) Active (9)
✅IV azithromycin + ceftriaxone + oral azithromycin + IV levofloxacin + oral levofloxacinPfizerApproved
✅TelithromycinSanofiApproved
🔄Ceftaroline + CeftriaxonePfizerPhase 3
🔄Azithromycin microspheres 2.0 single dosePfizerPhase 3
🔄tigecyclinePfizerPhase 3
🔄Azithromycin SRPfizerPhase 3
❌Tigecycline + Tigecycline + cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside + CAP: Ceftriaxone, plus if applicable oral clarithromycinPfizerPhase 3

Hype Score Breakdown

Clinical
12
Activity
4
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00270517Phase 2UNKNOWN

Competing Products

17 competing products in Community Acquired Pneumonia

See all competitors
ProductCompanyStageHype Score
ONO-5046Na + ONO-5046NaOno PharmaceuticalPhase 2
35
Ticagrelor + PlaceboAstraZenecaPhase 2
27
Ceftaroline + CeftriaxonePfizerPhase 3
40
Azithromycin microspheres 2.0 single dosePfizerPhase 3
40
tigecyclinePfizerPhase 3
40
IV azithromycin + ceftriaxone + oral azithromycin + IV levofloxacin + oral levofloxacinPfizerApproved
43
Azithromycin SRPfizerPhase 3
40
Tigecycline + Tigecycline + cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside + CAP: Ceftriaxone, plus if applicable oral clarithromycinPfizerPhase 3
32
Azithromycin SR + AmoxiclavPfizerPre-clinical
18
Tigecycline + Tigecycline + cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside + CAP: Ceftriaxone, plus if applicable oral clarithromycinPfizerPhase 3
32
tigecyclinePfizerPhase 3
40
Zinforo (ceftaroline fosamil)PfizerPre-clinical
26
Tigecycline + LevofloxacinPfizerPhase 3
40
AzithromycinPfizerPhase 3
40
TelithromycinSanofiApproved
43
Omadacycline + MoxifloxacinZai LabPhase 3
41
ceftobiprole medocaril + IV standard-of-care cephalosporinBasilea PharmaceuticaPhase 3
34